FACIAL FINE WRINKLING AND HYPERPIGMENTATION – UNMASKING INNER BEAUTY.  Tazarotene also has proven effective in treating skin damage resulting from chronic exposure to the sun. Unlike treatments that merely exfoliate and moisturize the skin, AVAGE (tazarotene cream 0.1%) is proven to significantly reduce some of the specific signs of photodamage, or overexposure to the sun. Although AVAGE does not reverse this process, it provides significant improvement in the appearance of the skin. AVAGE effectively reduces facial fine wrinkling and mottled hyperpigmentation when combined with comprehensive skin care and sunlight avoidance programs.  We have always believed that the tazarotene molecule is the most potent retinoid on the market, and the clinical studies continue to underscore that belief. One of the most recent studies comparing AVAGE to Renova illustrated that 80 percent of AVAGE patients showed improvement of at least one grade versus 61 percent for Renova in signs of photodamage. GENERAL SKIN CARE – A HEALTHY GLOW. Combined with Allergan’s other aesthetic skin care products, our comprehensive MD FORTE product line offers patients a customized skin care regimen that promises enhanced results. MD FORTE is a physician-dispensed line of aesthetic skin care products that provide benefits for all skin types as well as special skin conditions such as problem-prone acne skin, pre-procedure and post-procedure skin, photo- damaged skin and hyperpigmentation. The cleansers work to gently and effectively wash away oil, makeup and surface debris without drying skin. The renewal products diminish the appearance of fine lines and wrinkles while improving skin tone to produce younger, healthier-looking skin. The hydration products quench the skin’s thirst for moisture to produce softer, more supple skin, while our protection products provide UVA/UVB protection for complete coverage against future skin damage. Other key products in Allergan’s skin care line include AZELEX (azelaic acid cream 20%), indicated for mild-to-mod- erate acne and FLUOROPLEX (fluorouracil 1% topical cream), approved for the treatment of actinic (solar) keratoses (small red or skin-color growths that appear as a result of overexposure to the sun). In addition, in 2003 Allergan entered into a collaboration with Berlex, Inc. to jointly promote Berlex’s topical rosacea treatment, FINACEA (azelaic acid gel 15%). FINACEA is the first new therapeutic class option to be approved for the treatment of rosacea in more than a decade and has rapidly gained a leading position in the market.